» Articles » PMID: 34638601

Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Oct 13
PMID 34638601
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is a predominant malignancy worldwide, being the fourth most common cause of mortality and morbidity. The CRC incidence in adolescents, young adults, and adult populations is increasing every year. In the pathogenesis of CRC, various factors are involved including diet, sedentary life, smoking, excessive alcohol consumption, obesity, gut microbiota, diabetes, and genetic mutations. The CRC tumor microenvironment (TME) involves the complex cooperation between tumoral cells with stroma, immune, and endothelial cells. Cytokines and several growth factors (GFs) will sustain CRC cell proliferation, survival, motility, and invasion. Epidermal growth factor receptor (EGFR), Insulin-like growth factor -1 receptor (IGF-1R), and Vascular Endothelial Growth Factor -A (VEGF-A) are overexpressed in various human cancers including CRC. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) and all the three major subfamilies of the mitogen-activated protein kinase (MAPK) signaling pathways may be activated by GFs and will further play key roles in CRC development. The main aim of this review is to present the CRC incidence, risk factors, pathogenesis, and the impact of GFs during its development. Moreover, the article describes the relationship between EGF, IGF, VEGF, GFs inhibitors, PI3K/AKT/mTOR-MAPK signaling pathways, and CRC.

Citing Articles

Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.

Haynes J, Manogaran P Int J Mol Sci. 2025; 26(5).

PMID: 40076613 PMC: 11901061. DOI: 10.3390/ijms26051988.


Investigating the PI3K/AKT/mTOR axis in Buzhong Yiqi Decoction's anti-colorectal cancer activity.

Qiao S, Li X, Yang S, Hua H, Mao C, Lu W Sci Rep. 2025; 15(1):8238.

PMID: 40065054 PMC: 11893811. DOI: 10.1038/s41598-025-89018-9.


CNPY3's regulation of tumor microenvironment and its impact on colon cancer aggressiveness.

Gao X, Zhou B, Feng X, Ji Z, Li Q, Liu H Mol Med. 2025; 31(1):89.

PMID: 40055606 PMC: 11887163. DOI: 10.1186/s10020-025-01145-1.


Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm.

Gharaee N, Wegrzyn-Woltosz J, Jiang J, Akhade V, Bridgers J, Stubbins R Leukemia. 2025; .

PMID: 40000845 DOI: 10.1038/s41375-025-02537-2.


Emerging role of bile acids in colorectal liver metastasis: From molecular mechanism to clinical significance (Review).

Li Z, Deng L, Cheng M, Ye X, Yang N, Fan Z Int J Oncol. 2025; 66(3).

PMID: 39981904 PMC: 11844338. DOI: 10.3892/ijo.2025.5730.


References
1.
Timar J, Kashofer K . Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 2020; 39(4):1029-1038. PMC: 7680318. DOI: 10.1007/s10555-020-09915-5. View

2.
Ganesan K, Jayachandran M, Xu B . Diet-Derived Phytochemicals Targeting Colon Cancer Stem Cells and Microbiota in Colorectal Cancer. Int J Mol Sci. 2020; 21(11). PMC: 7312951. DOI: 10.3390/ijms21113976. View

3.
Bardou M, Barkun A, Martel M . Obesity and colorectal cancer. Gut. 2013; 62(6):933-47. DOI: 10.1136/gutjnl-2013-304701. View

4.
Wachsmannova L, Mego M, Stevurkova V, Zajac V, Ciernikova S . Novel strategies for comprehensive mutation screening of the APC gene. Neoplasma. 2017; 64(3):338-343. DOI: 10.4149/neo_2017_303. View

5.
Cornish A, Tomlinson I, Houlston R . Mendelian randomisation: A powerful and inexpensive method for identifying and excluding non-genetic risk factors for colorectal cancer. Mol Aspects Med. 2019; 69:41-47. PMC: 6856712. DOI: 10.1016/j.mam.2019.01.002. View